Tag: CAR T-cell
After CAR T-Cell Relapse in Mantle Cell Lymphoma, a CD79b-Targeted ADC...
A single-patient case report describes a prolonged remission with polatuzumab vedotin (Polivy®; Genentech/Roche) plus bendamustine (Treanda®; Teva/Cephalon) and rituximab (Rituxan®; Genentech/Biogen) in mantle cell lymphoma (MCL) after CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The regimen is approved for diffuse large B-cell lymphoma, not mantle cell lymphoma, and its use in this setting remains investigational.
Novartis Plans to Acquire Endocyte to Expand Expertise in Radiopharmaceuticals
Novartis announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted therapeutics...
